Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Sacubitril-Valsartan on Pulmonary Artery Systolic Pressure in HFrEF
NCT07814482Phase 1Completed
- Sponsor
- Aswan University
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Aswan University. Primary endpoint: Estimated Pulmonary Artery Systolic Pressure at 1 year. Started Jul 2025; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07814482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814482.